{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:19:11Z","timestamp":1790957951373,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejpb.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T15:11:37Z","timestamp":1658243497000},"page":"35-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Cyclodextrin-based delivery systems in parenteral formulations: A critical update review"],"prefix":"10.1016","volume":"178","author":[{"given":"Laura","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cl\u00e1udia","family":"Paiva-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.07.007_b0005","unstructured":"P.V. Arnum, Market View: Parenteral Drugs, 2019."},{"key":"10.1016\/j.ejpb.2022.07.007_b0010","unstructured":"Parenteral Drugs Market to Exhibit 6% CAGR, on Back of Surging Demand for Self-administered Drugs, 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0015","unstructured":"Parenteral Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029, 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0020","series-title":"Introduction to Parenteral Preparations, Concepts in sterile preparations and aseptic technique","first-page":"2","author":"Ochoa","year":"2015"},{"key":"10.1016\/j.ejpb.2022.07.007_b0025","unstructured":"M.J. Akers, Parenteral preparations, L.A. Felton (Ed.) Remington: Essentials of Pharmaceutics, Pharmaceutical Press, 2013."},{"key":"10.1016\/j.ejpb.2022.07.007_b0030","unstructured":"R.I. Mahato, A.S. Narang, Parenteral Drug Products, R.I. Mahato, A.S. Narang (Eds.) Pharmaceutical Dosage Forms and Drug Delivery, Taylor & Francis Group, Boca Raton, FL, 2017, pp. 533-541."},{"key":"10.1016\/j.ejpb.2022.07.007_b0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1517\/17425240903307423","article-title":"Recent advances in intravenous delivery of poorly water-soluble compounds","volume":"6","author":"Shi","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.07.007_b0040","series-title":"Formulating Poorly Water Soluble Drugs","first-page":"257","article-title":"Injectable Formulations of Poorly Water-Soluble Drugs","author":"Naguib","year":"2016"},{"key":"10.1016\/j.ejpb.2022.07.007_b0045","doi-asserted-by":"crossref","unstructured":"J.C.d. Miranda, T.E.A. Martins, F. Veiga, H.G. Ferraz, Cyclodextrins and ternary complexes: technology to improve solubility of poorly soluble drugs, Brazilian Journal of Pharmaceutical Sciences, 47 (2011) 665-681.","DOI":"10.1590\/S1984-82502011000400003"},{"key":"10.1016\/j.ejpb.2022.07.007_b0050","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"International journal of pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.07.007_b0055","unstructured":"A.E.d.M. (EMA), Anexo I - Resumo das Caracter\u00edsticas do Medicamento - Dynastat\u00ae. 22th June 2021."},{"key":"10.1016\/j.ejpb.2022.07.007_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119396","article-title":"Sulfobutylether-\u03b2-cyclodextrin","volume":"583","author":"Stella","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0065","unstructured":"Dexolve\u2122 (SBECD), Cyclolab 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0070","unstructured":"New monograph on Sulfobutylbetadex sodium (2804), Strasbourg, France, 2018."},{"key":"10.1016\/j.ejpb.2022.07.007_b0075","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.xphs.2020.10.026","article-title":"Cyclodextrins in Parenteral Formulations","volume":"110","author":"Loftsson","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0080","unstructured":"C.o.t.e.o.t.E. Pharmacopoeia, European Pharmacopoeia, 8th Edition ed., Directorate for the Quality of Medicines as Healthcare of the Council of Europe, Strasbourg, 2013."},{"key":"10.1016\/j.ejpb.2022.07.007_b0085","doi-asserted-by":"crossref","unstructured":"M.J. Akers, Sterile Drug Products, CRC Press, 2016. https:\/\/doi.org\/10.3109\/9781420020564.","DOI":"10.3109\/9781420020564"},{"key":"10.1016\/j.ejpb.2022.07.007_b0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.07.007_b0095","series-title":"Parenteral Dosage Forms: Introduction and Historical perspective","first-page":"1","article-title":"Pharmaceutical Dosage Forms - Parenteral Medications","author":"Ludwig","year":"2010"},{"key":"10.1016\/j.ejpb.2022.07.007_b0100","doi-asserted-by":"crossref","DOI":"10.1213\/ANE.0000000000000559","article-title":"Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether-\u03b2-Cyclodextrin","volume":"120","author":"Goodchild","year":"2015","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejpb.2022.07.007_b0105","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1039\/C9SC00375D","article-title":"NIR-II light-modulated thermosensitive hydrogel for light-triggered cisplatin release and repeatable chemo-photothermal therapy","volume":"10","author":"Ruan","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0110","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.xphs.2016.05.010","article-title":"Cyclodextrin-Mediated Hierarchical Self-Assembly and Its Potential in Drug Delivery Applications","volume":"105","author":"Antoniuk","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jiec.2018.09.052","article-title":"Engineered beta-cyclodextrin-based carrier for targeted doxorubicin delivery in breast cancer therapy in vivo","volume":"70","author":"Hyun","year":"2019","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.ejpb.2022.07.007_b0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2003.11.034","article-title":"Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin","volume":"272","author":"Kim","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2019.111151","article-title":"Inclusion complex of emodin with hydroxypropyl-\u03b2-cyclodextrin: Preparation, physicochemical and biological properties","volume":"289","author":"Qiu","year":"2019","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2022.07.007_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119019","article-title":"Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic properties","volume":"576","author":"Laine","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejps.2017.09.025","article-title":"Development and pharmaceutical evaluation of the anticancer Anthrafuran\/Cavitron complex, a prototypic parenteral drug formulation","volume":"109","author":"Treshalina","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijpharm.2011.10.022","article-title":"Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-beta-cyclodextrin","volume":"422","author":"Uehata","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.colsurfb.2013.11.025","article-title":"A characterization study of resveratrol\/sulfobutyl ether-\u03b2-cyclodextrin inclusion complex and in vitro anticancer activity","volume":"115","author":"Venuti","year":"2014","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.ejpb.2022.07.007_b0150","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1039\/C8PY00730F","article-title":"Cyclodextrin-based host-guest supramolecular hydrogel and its application in biomedical fields","volume":"9","author":"Liu","year":"2018","journal-title":"Polym. Chem."},{"key":"10.1016\/j.ejpb.2022.07.007_b0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.colsurfb.2016.01.034","article-title":"An injectable, dual pH and oxidation-responsive supramolecular hydrogel for controlled dual drug delivery","volume":"141","author":"Cheng","year":"2016","journal-title":"Colloid Surf. B-Biointerfaces"},{"key":"10.1016\/j.ejpb.2022.07.007_b0160","first-page":"769","article-title":"Verfahren zur Herstellung von Einschlussverbindungen physiologisch wirksamer organischer Verbindungen","author":"Freudenberg","year":"1953","journal-title":"Germany"},{"key":"10.1016\/j.ejpb.2022.07.007_b0165","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.addr.2011.08.003","article-title":"Protein stabilization by cyclodextrins in the liquid and dried state","volume":"63","author":"Serno","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.07.007_b0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpharm.2016.07.030","article-title":"Thirty years with cyclodextrins","volume":"514","author":"Duch\u00eane","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0175","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: Past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2022.07.007_b0180","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.drudis.2015.11.017","article-title":"Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.ejpb.2022.07.007_b0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.06.055","article-title":"Cyclodextrins","volume":"453","author":"Kurkov","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2022.07.007_b0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.drudis.2015.11.016","article-title":"Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiency","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.ejpb.2022.07.007_b0200","unstructured":"Chemical book."},{"key":"10.1016\/j.ejpb.2022.07.007_b0205","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1208\/s12249-010-9482-0","article-title":"Parenteral Delivery of HP beta CD: Effects on Drug-HSA Binding","volume":"11","author":"Kurkov","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2022.07.007_b0210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jphp.12427","article-title":"Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug\/cyclodextrin complexes","volume":"68","author":"Loftsson","year":"2016","journal-title":"J. Pharmacy Pharmacol."},{"key":"10.1016\/j.ejpb.2022.07.007_b0215","first-page":"111","article-title":"L. D, Pharmacokinetics of dextrans","author":"Deux","year":"2001","journal-title":"Curr. Trends Polym. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0220","first-page":"307","article-title":"Self-assembly of cyclodextrin complexes: detection, obstacles and benefits","volume":"75","author":"Muankaew","year":"2020","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2022.07.007_b0225","unstructured":"Background review for cyclodextrins used as excipients., EMA (Ed.), 2014."},{"key":"10.1016\/j.ejpb.2022.07.007_b0230","unstructured":"C.f.H.M.P. (CHMP), Cyclodextrins used as excipients, European Medicines Agency, London, 2017."},{"key":"10.1016\/j.ejpb.2022.07.007_b0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.12.021","article-title":"Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity","volume":"319","author":"Kim","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.07.007_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.108073","article-title":"Hydroxypropyl-\u03b2-cyclodextrin causes massive damage to the developing auditory and vestibular system","volume":"396","author":"Ding","year":"2020","journal-title":"Hear. Res."},{"key":"10.1016\/j.ejpb.2022.07.007_b0245","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejps.2016.06.012","article-title":"Inclusion complexation with \u03b2-cyclodextrin derivatives alters photodynamic activity and biodistribution of meta-tetra(hydroxyphenyl)chlorin","volume":"91","author":"Yankovsky","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.07.007_b0255","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.xphs.2018.03.021","article-title":"Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems","volume":"107","author":"Shelley","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1773-2247(12)50032-8","article-title":"Self-assembly of cyclodextrins: formation of cyclodextrin polymer based nanoparticles","volume":"22","author":"F\u00fcl\u00f6p","year":"2012","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.07.007_b0265","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0169-409X(98)00057-X","article-title":"Cyclodextrins in peptide and protein delivery","volume":"36","author":"Irie","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.07.007_b0270","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.carbpol.2016.05.100","article-title":"Probing inclusion complexes of cyclodextrins with amino acids by physicochemical approach","volume":"151","author":"Roy","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2022.07.007_b0275","doi-asserted-by":"crossref","first-page":"42383","DOI":"10.1039\/C4RA07877B","article-title":"Host\u2013guest inclusion complexes of \u03b1 and \u03b2-cyclodextrins with \u03b1-amino acids","volume":"4","author":"Roy","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2022.07.007_b0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/polym11030514","article-title":"Supramolecular Cyclodextrin-Based Hydrogels for Controlled Gene Delivery","volume":"11","author":"Rey-Rico","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.ejpb.2022.07.007_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092097","article-title":"Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy","volume":"20","author":"Bai","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nantod.2010.06.011","article-title":"Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications","volume":"5","author":"Zhang","year":"2010","journal-title":"Nano Today"},{"key":"10.1016\/j.ejpb.2022.07.007_b0295","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1021\/bm901065f","article-title":"Cyclodextrin-Based Polymeric Materials: Synthesis, Properties, and Pharmaceutical\/Biomedical Applications","volume":"10","author":"van de Manakker","year":"2009","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2022.07.007_b0300","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1039\/c0py00219d","article-title":"Cyclodextrin functionalized polymers as drug delivery systems","volume":"1","author":"Zhou","year":"2010","journal-title":"Polym. Chem."},{"key":"10.1016\/j.ejpb.2022.07.007_b0305","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.actbio.2019.07.024","article-title":"An injectable thermosensitive photothermal-network hydrogel for near-infrared-triggered drug delivery and synergistic photothermal-chemotherapy","volume":"96","author":"Liu","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2022.07.007_b0310","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejpb.2011.12.007","article-title":"Self-assembled biotransesterified cyclodextrins as Artemisinin nanocarriers - I: Formulation, lyoavailability and in vitro antimalarial activity assessment","volume":"80","author":"Yameogo","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0315","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1039\/C9TB00120D","article-title":"An injectable nanocomposite hydrogel co-constructed with gold nanorods and paclitaxel-loaded nanoparticles for local chemo-photothermal synergetic cancer therapy","volume":"7","author":"Liu","year":"2019","journal-title":"J. Mat. Chem. B"},{"key":"10.1016\/j.ejpb.2022.07.007_b0320","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1039\/C6BM00889E","article-title":"Supramolecular hydrogel based on high-solid-content mPECT nanoparticles and cyclodextrins for local and sustained drug delivery","volume":"5","author":"Yin","year":"2017","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0325","first-page":"5397","article-title":"Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-\u03b2-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection","volume":"10","author":"Baek","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2022.07.007_b0330","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.msec.2015.12.098","article-title":"Hydroxypropyl-beta-cyclodextrin-graphene oxide conjugates: Carriers for anti-cancer drugs","volume":"61","author":"Tan","year":"2016","journal-title":"Mater. Sci. Eng. C-Mater. Biol. Appl."},{"key":"10.1016\/j.ejpb.2022.07.007_b0335","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.carbpol.2019.04.024","article-title":"Biotin and arginine modified hydroxypropyl-\u03b2-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel","volume":"216","author":"Yan","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2022.07.007_b0340","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1021\/bm300936x","article-title":"Supramolecular Anchoring of DNA Polyplexes in Cyclodextrin-Based Polypseudorotaxane Hydrogels for Sustained Gene Delivery","volume":"13","author":"Li","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2022.07.007_b0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/1061186X.2013.856012","article-title":"Potential use of the complex of doxorubicin with folate-conjugated methyl-beta-cyclodextrin for tumor-selective cancer chemotherapy","volume":"22","author":"Motoyama","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2022.07.007_b0350","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1002\/jps.23234","article-title":"Sufentanil-2-hydroxypropyl-beta-cyclodextrin inclusion complex for pain treatment: Physicochemical, cytotoxicity, and pharmacological evaluation","volume":"101","author":"Volobuef","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0355","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.xphs.2019.01.004","article-title":"Cyclodextrin Reduces Intravenous Toxicity of a Model Compound","volume":"108","author":"Mantik","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0360","doi-asserted-by":"crossref","unstructured":"V.M. Couto, L. Oliveira-Nascimento, Capsaicin-Cyclodextrin Complex Enhances Mepivacaine Targeting and Improves Local Anesthesia in Inflamed Tissues, 21 (2020). https:\/\/doi.org\/10.3390\/ijms21165741.","DOI":"10.3390\/ijms21165741"},{"key":"10.1016\/j.ejpb.2022.07.007_b0365","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.xphs.2016.04.033","article-title":"In Vitro and In Vivo Evaluation of Hydrophilic C-60(OH)(10)\/2-Hydroxypropyl-beta-cyclodextrin Nanoparticles as an Antioxidant","volume":"105","author":"Iohara","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2011.07.018","article-title":"Effect of sulfobutyl ether-beta-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats","volume":"419","author":"Uehata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0375","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1021\/acs.jcim.6b00215","article-title":"Characterization, in Vivo Evaluation, and Molecular Modeling of Different Propofol-Cyclodextrin Complexes To Assess Their Drug Delivery Potential at the Blood-Brain Barrier Level","volume":"56","author":"Shityakov","year":"2016","journal-title":"J. Chem Inf. Model."},{"key":"10.1016\/j.ejpb.2022.07.007_b0380","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2017.01.038","article-title":"A novel injectable formulation of 6-fluoro-(L)-DOPA imaging agent for diagnosis of neuroendocrine tumors and Parkinson's disease","volume":"519","author":"Trapani","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0385","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1002\/jps.22496","article-title":"Development of Pegylated Liposomal Vincristine Using Novel Sulfobutyl Ether Cyclodextrin Gradient: Is Improved Drug Retention Sufficient to Surpass DSPE-PEG-Induced Drug Leakage?","volume":"100","author":"Cui","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0390","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s11095-014-1551-8","article-title":"Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug","volume":"32","author":"Zhang","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.07.007_b0395","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijpharm.2012.01.054","article-title":"Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-beta-cyclodextrin inclusion complex-loaded albumin nanoparticles","volume":"427","author":"Gao","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0400","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.05.049","article-title":"Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice","volume":"235","author":"Dou","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.07.007_b0405","doi-asserted-by":"crossref","first-page":"42622","DOI":"10.1021\/acsami.7b14963","article-title":"Versatile Supermolecular Inclusion Complex Based on Host Guest Interaction for Targeted Gene Delivery","volume":"9","author":"Sun","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2022.07.007_b0410","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2018.07.004","article-title":"Injectable and protease-degradable hydrogel for siRNA sequestration and triggered delivery to the heart","volume":"285","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.07.007_b0415","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.msec.2016.06.058","article-title":"Cyclodextrin-polyhydrazine degradable gels for hydrophobic drug delivery","volume":"69","author":"Jalalvandi","year":"2016","journal-title":"Mater. Sci. Eng. C-Mater. Biol. Appl."},{"key":"10.1016\/j.ejpb.2022.07.007_b0420","doi-asserted-by":"crossref","unstructured":"Abu Hashim, II, T. Higashi, T. Anno, K. Motoyama, A.E.H. Abd-ElGawad, M.H. El-Shabouri, T.M. Borg, H. Arima, Potential use of gamma-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin, International journal of pharmaceutics, 392 (2010) 83-91. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.03.026.","DOI":"10.1016\/j.ijpharm.2010.03.026"},{"key":"10.1016\/j.ejpb.2022.07.007_b0425","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1208\/s12249-014-0198-4","article-title":"Injectable Supramolecular Hydrogel from Insulin-Loaded Triblock PCL-PEG-PCL Copolymer and gamma-Cyclodextrin with Sustained-Release Property","volume":"16","author":"Khodaverdi","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2022.07.007_b0430","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.xphs.2017.01.002","article-title":"Stabilizing Effects for Antibody Formulations and Safety Profiles of Cyclodextrin Polypseudorotaxane Hydrogels","volume":"106","author":"Higashi","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0435","doi-asserted-by":"crossref","first-page":"15857","DOI":"10.1021\/acsami.6b02562","article-title":"Light-Induced Hydrogel Based on Tumor-Targeting Mesoporous Silica Nanoparticles as a Theranostic Platform for Sustained Cancer Treatment","volume":"8","author":"Chen","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2022.07.007_b0440","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.addr.2011.03.005","article-title":"Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions","volume":"64","author":"Alkilany","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.07.007_b0445","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/13543776.2015.1045412","article-title":"Cyclodextrins: improving the therapeutic response of analgesic drugs: a patent review","volume":"25","author":"de Oliveira","year":"2015","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.ejpb.2022.07.007_b0450","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/jphp.12703","article-title":"Complexation of oxethazaine with 2-hydroxypropyl-beta-cyclodextrin: increased drug solubility, decreased cytotoxicity and analgesia at inflamed tissues","volume":"69","author":"Prado","year":"2017","journal-title":"J. Pharmacy Pharmacol."},{"key":"10.1016\/j.ejpb.2022.07.007_b0455","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1055\/a-1013-1276","article-title":"Development and Characterization of the Neuroregenerative Xanthohumol C\/Hydroxypropyl- beta -cyclodextrin Complex Suitable for Parenteral Administration","volume":"85","author":"Kirchinger","year":"2019","journal-title":"Planta Med."},{"key":"10.1016\/j.ejpb.2022.07.007_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105034","article-title":"NLG919\/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel","volume":"138","author":"Xu","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0465","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040240","article-title":"Designing a Formulation of the Nootropic Drug Aniracetam Using 2-Hydroxypropyl-beta-Cyclodextrin Suitable for Parenteral Administration","volume":"10","author":"Goldsmith","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.07.007_b0470","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2015.02.026","article-title":"Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation","volume":"203","author":"Zhang","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.07.007_b0475","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1002\/adfm.201400011","article-title":"Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site-and Sequence-Specific Drug Release","volume":"24","author":"Ruiz-Esparza","year":"2014","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2022.07.007_b0480","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijpharm.2017.07.007","article-title":"New nanoparticles obtained by co-assembly of amphiphilic cyclodextrins and nonlamellar single-chain lipids: Preparation and characterization","volume":"531","author":"Nguyen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0485","doi-asserted-by":"crossref","unstructured":"P. Perret, S. Bacot, A. G\u00e8ze, A. Gentil Dit Maurin, M. Debiossat, A. Soubies, V. Blanc-Marquis, L. Choisnard, J. Boutonnat, C. Ghezzi, J.L. Putaux, C. Lancelon-Pin, L.M. Riou, D. Wouessidjewe, Biodistribution and preliminary toxicity studies of nanoparticles made of Biotransesterified \u03b2\u2013cyclodextrins and PEGylated phospholipids, Materials Science and Engineering: C, 85 (2018) 7-17. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.msec.2017.12.017.","DOI":"10.1016\/j.msec.2017.12.017"},{"key":"10.1016\/j.ejpb.2022.07.007_b0490","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2016.10.062","article-title":"gamma-Cyclodextrin","volume":"516","author":"Saokham","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0495","first-page":"6","article-title":"Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic gamma-cyclodextrin nanoparticles","volume":"106","author":"Yameogo","year":"2020","journal-title":"Mater. Sci. Eng. C-Mater. Biol. Appl."},{"key":"10.1016\/j.ejpb.2022.07.007_b0500","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/phar.1304","article-title":"Single-Dose and Multiple-Dose Pharmacokinetics and Dose Proportionality of Intravenous and Intramuscular HP beta CD-Diclofenac (Dyloject) Compared with Other Diclofenac Formulations","volume":"33","author":"Mermelstein","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejpb.2022.07.007_b0505","unstructured":"Drugs@FDA: FDA-Approved Drugs."},{"key":"10.1016\/j.ejpb.2022.07.007_b0510","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/pme.12076","article-title":"Safety of a Novel Parenteral Formulation of Diclofenac after Major Orthopedic or Abdominal\/Pelvic Surgery in a Population Including Anticoagulated, Elderly or Renally Insufficient Patients: An Open-Label, Multiday, Repeated Dose Clinical Trial","volume":"14","author":"Chelly","year":"2013","journal-title":"Pain Med."},{"key":"10.1016\/j.ejpb.2022.07.007_b0515","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40266-018-0529-3","article-title":"Safety of Injectable HP beta CD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials","volume":"35","author":"Chelly","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejpb.2022.07.007_b0520","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jclinane.2016.01.020","article-title":"Cardiovascular safety of hydroxypropyl-beta-cyclodextrin-diclofenac in the management of acute postsurgical pain: a pooled analysis of 2 randomized, double-blind, placebo- and active comparator-controlled phase III clinical trials","volume":"31","author":"Gan","year":"2016","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.ejpb.2022.07.007_b0525","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1093\/pm\/pnw146","article-title":"A Pooled Analysis Evaluating Renal Safety in Placebo-and Active Comparator-Controlled Phase III Trials of Multiple-Dose Injectable HP beta CD-Diclofenac in Subjects with Acute Postoperative Pain","volume":"17","author":"Daniels","year":"2016","journal-title":"Pain Med."},{"key":"10.1016\/j.ejpb.2022.07.007_b0530","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12483","article-title":"Intravenous Hydroxypropyl beta-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial","volume":"10","author":"Erb-Zohar","year":"2017","journal-title":"CTS-Clin. Transl. Sci."},{"key":"10.1016\/j.ejpb.2022.07.007_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119689","article-title":"The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2","volume":"588","author":"Garrido","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.007_b0540","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13054-015-0753-8","article-title":"Evaluation of sulfobutylether-beta-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy","volume":"19","author":"Kiser","year":"2015","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejpb.2022.07.007_b0545","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/myc.12517","article-title":"Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether -cyclodextrin in haematological patients with renal impairment","volume":"59","author":"Kim","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.ejpb.2022.07.007_b0550","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jcph.1077","article-title":"Clinical Pharmacokinetics of Sulfobutylether-beta-Cyclodextrin in Patients With Varying Degrees of Renal Impairment","volume":"58","author":"Hoover","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2022.07.007_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.clindermatol.2020.05.015","article-title":"Remdesivir - A giant step, or a tiptoe?","author":"Dickinson","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejpb.2022.07.007_b0560","unstructured":"C.f.M.P.f.H.U. (CHMP), Veklury, European Medicines Agency, Amsterdam, 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0565","unstructured":"Fact sheet for health care providers Emergency use authorization (EUA) of Veklury (remdesivir), Food and Drug Administration, 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0570","doi-asserted-by":"crossref","unstructured":"J.D. Goldman, D.C.B. Lye, D.S. Hui, K.M. Marks, R. Bruno, R. Montejano, C.D. Spinner, M. Galli, M.Y. Ahn, R.G. Nahass, Y.S. Chen, D. SenGupta, R.H. Hyland, A.O. Osinusi, H. Cao, C. Blair, X. Wei, A. Gaggar, D.M. Brainard, W.J. Towner, J. Mu\u00f1oz, K.M. Mullane, F.M. Marty, Remdesivir for 5 or 10 Days in Patients with Severe Covid-19, (2020). https:\/\/doi.org\/10.1056\/NEJMoa2015301.","DOI":"10.1056\/NEJMoa2015301"},{"key":"10.1016\/j.ejpb.2022.07.007_b0575","unstructured":"Veklury (remdesivir) - An overview of Veklury and why it is authorised in the EU, European Medicines Agency, Amsterdam, 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir","volume":"201","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2022.07.007_b0585","article-title":"Approved pharmaceutical products containing cyclodextrins","volume":"27","author":"Fenyvesi","year":"2013","journal-title":"Cyclodextrin News"},{"key":"10.1016\/j.ejpb.2022.07.007_b0590","unstructured":"U.S.D.o.H.a.H. Services, Approved drug products with therapeutic equivalence evaluations, F.a.D.A. (FDA) (Ed.), 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0595","unstructured":"PREVYMIS (letermovir) Tablets and PREVYMIS (letermovir) Injection, 2017."},{"key":"10.1016\/j.ejpb.2022.07.007_b0600","unstructured":"FULL PRESCRIBING INFORMATION- Zulresso, 2019."},{"key":"10.1016\/j.ejpb.2022.07.007_b0605","unstructured":"Kyprolis (carfilzomib) for Injection, 2012."},{"key":"10.1016\/j.ejpb.2022.07.007_b0610","unstructured":"Review Reports: Drugs, 2020."},{"key":"10.1016\/j.ejpb.2022.07.007_b0615","unstructured":"The pharmaceuticals and Medical Devices Agency Anual Report FY 2014, 2014."},{"key":"10.1016\/j.ejpb.2022.07.007_b0620","unstructured":"The pharmaceuticals and Medical Devices Agency Anual Report FY 2015, 2015."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112200145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112200145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:47:41Z","timestamp":1760546861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112200145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":124,"alternative-id":["S093964112200145X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.07.007","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclodextrin-based delivery systems in parenteral formulations: A critical update review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}